ANZCTR search results

This study aims to investigate whether eating mussels as a snack can improve recovery and nutritional status in female endurance athletes. Participants will consume either mussels or an isocaloric portion of nuts five times per week for 12 weeks. We will measure omega-3 index, iron status, vitamin D levels, and post-exercise recovery to compare the effects of the two snacks. We hypothesise that mussel consumption will lead to greater improvements in these health markers compared to nuts. The findings may help support new dietary strategies to enhance athletic recovery using sustainable whole foods.

Young adults have the poorest diet quality out of all age groups, however, are motivated towards climate action. A potential way to improve their diets is to promote healthy and sustainable diets in this group. This study involves the development of a targeted healthy and sustainable nutrition program for young adults, and an assessment of its feasibility. It is expected that the program will have acceptable feasibility i.e. high response rates and low drop out rates.

This study is to investigate the safety, tolerability, and PK of EIK1005 in healthy participants. EIK1005 is a potent and selective inhibitor of WRN, which has been identified as a synthetic lethal target in MSI-H cells. MSI-H is a marker of cancer cells with defective mismatch repair. WRN inhibition (WRNi) acts on MSI-H cells, and thus WRNi is not expected to have an effect on healthy tissue. EIK1005 is noncytotoxic and is been considered has as potential targeted therapy in patients with MSI-H or dMMR solid tumors.

The primary purpose of the study is to assess the safety and tolerability of a single oral dose of EP102 200 mg or 400 mg self-administered at home by adult participants experiencing moderate-to-severe migraine headache.

The present study aimed to evaluate the impact of the Body Blocks program on early learning educators’ knowledge, attitudes, and teaching practices by conducting a randomised controlled trial, with participants randomised to either an intervention group or waitlist control. We anticipated that participants randomised to the intervention group would report higher educator knowledge and attitudes about body image compared to educators in the waitlist control group, as well as greater confidence and capabilities in promoting positive body image. In addition, we explored the moderating role of demographic variables (i.e., age, years in the profession, socio-economic-status), as well as educators’ own body and functionality appreciation and fat attitudes on our main outcome of interest (i.e., knowledge and awareness).

Temperament-Based Therapy with Support (TBT-S) is an innovative, adjunctive eating disorder treatment that incorporates the neurobiology of eating disorders. Patients and their support person(s) attend a 5 day intensive multi-family therapy program that involves psychoeducation, group activities and meals. This study will investigate both the feasibility and acceptability of the TBT-S program in Victorian mental health services from the experience of the patient, their support person and the clinicians involved in the program. It is hypothesised that TBT-S will be an acceptable and feasible treatment option for patients and their supports.

Binge eating disorder (BED) is the most common eating disorder and is associated with obesity and psychiatric comorbidities. Psilocin taken in combination with talk therapy might be a useful treatment for BED by reducing overall anxiety, anxiety around food, perseveration, and repetitive and intrusive thinking, as well as improving mindfulness and self-compassion. This open-label study will evaluate the safety and efficacy of a novel intravenous (IV, i.e. into the vein) formulation of the psychedelic psilocin (TRP-8803) in 12 people with BED. IV administration of TRP-8803 permits a more rapid start to the psychedelic state compared to psilocin taken orally as a tablet, and allows the administering therapist to control and optimise the dose and if required, rapidly reduce the depth of the psychedelic experience by stopping the infusion (i.e., in case of an adverse effect). Eligible participants will complete two doses of TRP-8803, administered in conjunction with psychotherapy over a treatment period of 6 weeks, and followed up until 12 weeks post second dose. Safety will be assessed. Other indicators of clinical severity will also be explored from baseline through to 12 weeks post second dose.

The aim of this study is to test if third-line treatments for depression (MDD), should be prescribed earlier in the illness course, after a first-line treatment fails. This study is testing the idea (hypothesis) that medications that are usually only used third-line ( called Early Intensified Pharmacological Treatment - EIPT in this study) are more effective than the medications that currently get used second-line (Treatment As Usual - TAU). This study has a six-week duration and participants are randomised into either the EIPT or TAU group. Participants must have a regular treating doctor (GP or psychiatrist) who is willing to be contacted by the study team, and who will prescribe and manage the medication for all TAU participants, The study doctors will prescribe and dispense medication for EIPT participants in MDD. There are optional "opt-in' biodata, blood and stool samples that participants may choose to give; these are to help researchers identify predictors for treatment-resistance and treatment response.

In 2021 it is estimated that 744,800 people in Australia, are living with bipolar disorder and account for a significant proportion of the $11.6 billion spent on mental health related services in Australia in 2020-21 .When diagnosed with one of these disorders, patients are prescribed psychotropic medication such as antidepressants, mood stabilisers or antipsychotics. It is unknown whether this first-line treatment will be successful. After this first-line treatment fails, usually a second-line treatment is initiated, and when this is not successful either a third-line treatment is initiated. Third-line treatments are quite successful, especially when compared to second-line treatments. The research question is whether the third-line treatments (early intensified treatments) would be more efficacious than the current second-line treatments (treatment as usual) for schizophrenia, bipolar and major depressive disorders. If this is indeed the case, this could lead to the prevention of unnecessary trials of ineffective treatments and adaptations of worldwide guidelines as well as a reduction of healthcare and societal costs.

The aim of this study is to test if third-line treatments for Schizophrenia (SZ) should be prescribed earlier in the illness course, after a first-line treatment fails. This study is testing the idea (hypothesis) that medications that are usually only used third-line ( called Early Intensified Pharmacological Treatment - EIPT in this study) are more effective than the medications that currently get used second-line (Treatment As Usual - TAU). This study has a six-week duration and participants are randomised into either the EIPT or TAU group. Participants must have a regular treating doctor (GP or psychiatrist) who is willing to be contacted by the study team, and who will prescribe and manage the medication for all TAU participants, There are optional "opt-in' biodata, blood and stool samples that participants may choose to give; these are to help researchers identify predictors for treatment-resistance and treatment response.